Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abuse Potential of Dronabinol Oral Solution in Recreational Cannabinoid Users
NCT02094599Phase 1Completed
- Sponsor
- Insys Therapeutics
- Start
- Feb 2014
- Primary completion
- May 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of dronabinol in anorexia nervosa (AN) and chemotherapy-induced nausea and vomiting (CINV) (5 arms), sponsored by Insys Therapeutics. Primary endpoint: Peak score (Emax) on Drug Liking VAS at 24 hours. Started Feb 2014; status: completed.
02
Drugs
dronabinol
03
Conditions
anorexia nervosa (AN)chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NCT02094599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02094599.